ANALISIS KADAR SERUM FERITIN DI KARSINOMA PAYUDARA (Analysis of Ferritin Levels in Carcinoma Mammae)

Sriwati Atjo, Uleng Bahrun, Hardjoeno Hardjoeno


Carcinoma Mammae is a malignant disease originating from mammary parenchyma, and the second largest cause of death in
the world. Ferritin is a marker of neoplasia, which levels are increased in non-metastatic carcinoma mammae and more increased in
metastatic carcinoma mammae. This cross sectional study was conducted during June 2012 in carcinoma mammae patients of the
Wahidin Sudirohusodo Hospital, Ibnu Sina Hospital and Labuang Baji Hospital in Makassar. The aim of this study was to know the
serum ferritin levels in metastatic and non-metastatic carcinoma mammae. In this study, 56 samples were obtained and grouped into
metastatic and non-metastatic carcinoma mammae patients based on the Tumor, Node, Metastasis (TNM). Ferritin test was conducted
by ECLIA method using Elecsys Analyzer Kit 2010 (Roche, USA). The study showed that the average ferritin concentration in advanced
stage of carcinoma mammae (155.45 ng/mL) was higher than in the early stage (82.74 ng/m). The Mann Whitney test showed significant
differences between the early and advanced stage (p=0.01), the median ferritin value in metastatic carcinoma mammae was higher
than non-metastatic (79.85 ng/mL). The Mann Whitney test showed significant differences between metastatic and non - metastatic
carcinoma mammae patients (p=0.00). Based on this study, it can be concluded, that ferritin levels can be used as a biomarker to predict
the progressivity of carcinoma mammae.


Serum ferritin, carcinoma mammae, metastatic, non-metastatic

Full Text:




  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.